Sabina Cosulich
AstraZeneca (United Kingdom)(GB)The Francis Crick Institute(GB)AstraZeneca (Poland)(PL)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Advanced Breast Cancer Therapies, PARP inhibition in cancer therapy, Melanoma and MAPK Pathways, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity(2009)793 cited
- → Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor(2016)473 cited
- → Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells(2013)460 cited
- → Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)(2009)460 cited
- → Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background(2012)457 cited
- → Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer